RENALYTIX AI PLC-ADR (RNLX) Stock Overview
USA - NASDAQ:RNLX - US75973T1016 - ADR
RNLX Key Statistics, Chart & Performance
The current stock price of RNLX is 0.2071 USD. In the past month the price decreased by -26.3%. In the past year, price decreased by -82.15%.
RNLX Latest News, Press Relases and Analysis
RNLX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 39.11 | 47.76B | ||
| DOCS | DOXIMITY INC-CLASS A | 44.62 | 12.45B | ||
| WAY | WAYSTAR HOLDING CORP | 35.58 | 7.54B | ||
| HTFL | HEARTFLOW INC | N/A | 3.19B | ||
| CERT | CERTARA INC | 24.76 | 1.95B | ||
| SDGR | SCHRODINGER INC | N/A | 1.60B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.48B | ||
| PHR | PHREESIA INC | N/A | 1.40B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 10.46 | 1.27B | ||
| CTEV | CLARITEV CORP | N/A | 1.17B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.07B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | N/A | 899.72M |
Related stock screener links
About RNLX
Company Profile
Renalytix Plc engages in the manufacturing of medical devices and equipment. The firm is engaged in a field of bioprognosis for kidney health. The firm has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The company is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Company Info
RENALYTIX AI PLC-ADR
Finsgate, 5-7 Cranwood Street
London SOUTH GLAMORGAN CF64 2EZ GB
CEO: James McCullough
Employees: 102
Phone: 442920710570
RENALYTIX AI PLC-ADR / RNLX FAQ
What does RENALYTIX AI PLC-ADR do?
Renalytix Plc engages in the manufacturing of medical devices and equipment. The firm is engaged in a field of bioprognosis for kidney health. The firm has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The company is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Can you provide the latest stock price for RENALYTIX AI PLC-ADR?
The current stock price of RNLX is 0.2071 USD. The price increased by 5.66% in the last trading session.
Does RNLX stock pay dividends?
RNLX does not pay a dividend.
What is the ChartMill rating of RENALYTIX AI PLC-ADR stock?
RNLX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of RENALYTIX AI PLC-ADR (RNLX) based on its PE ratio?
RENALYTIX AI PLC-ADR (RNLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
Can you provide the market cap for RENALYTIX AI PLC-ADR?
RENALYTIX AI PLC-ADR (RNLX) has a market capitalization of 17.18M USD. This makes RNLX a Nano Cap stock.
When does RENALYTIX AI PLC-ADR (RNLX) report earnings?
RENALYTIX AI PLC-ADR (RNLX) will report earnings on 2024-10-29, after the market close.
RNLX Technical Analysis
RNLX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNLX. RNLX may be in some trouble as it scores bad on both profitability and health.
RNLX Financial Highlights
Over the last trailing twelve months RNLX reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 27.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -109.75% | ||
| ROE | -250.48% | ||
| Debt/Equity | 0.41 |
RNLX Forecast & Estimates
5 analysts have analysed RNLX and the average price target is 2.67 USD. This implies a price increase of 1187.44% is expected in the next year compared to the current price of 0.2071.
For the next year, analysts expect an EPS growth of 59.3% and a revenue growth 39.85% for RNLX